Clinical TrialAug 5, 2026, 08:23 AM
SciSparc Subsidiary NeuroThera Initiates Yale Clinical Trial Site
AI Summary
SciSparc Ltd.'s majority-owned subsidiary, NeuroThera Labs Inc., announced the initiation of a Phase IIb clinical trial site at the Yale Child Study Center for its proprietary cannabinoid-based drug candidate, SCI-110. This trial aims to evaluate SCI-110 for the treatment of Tourette Syndrome in adults, building on positive Phase IIa results that showed an average tic reduction of 21%. The drug combines dronabinol with palmitoylethanolamide and is also being studied at sites in Germany and Israel, representing a significant step in addressing an unmet medical need.
Key Highlights
- NeuroThera initiated a Phase IIb clinical trial site at Yale Child Study Center for SCI-110.
- The trial evaluates SCI-110 for the treatment of Tourette Syndrome in adults.
- SCI-110 is a cannabinoid-based drug combining dronabinol with palmitoylethanolamide.
- Other Phase IIb trial sites include Hannover Medical School and Tel Aviv Sourasky Medical Center.
- Phase IIa study showed an average tic reduction of 21% as measured by the Yale Global Tic Severity Scale.
- The Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial.
- Primary efficacy endpoint is the change in tic severity at weeks 12 and 26 compared to baseline.
Price Impact
More from SPRC